Bloomberg Shares of AstraZeneca Plc, the UK’s biggest drugmaker, started trading on the New York Stock Exchange on Monday following a listing upgrade to replace its American Depositary Receipts that were on Nasdaq. The drug and vaccine maker is seeking to attract more investors by tilting further toward the US, where it makes almost half of its revenue. It has said the move will give equal weight to its UK, Swedish and US listings. AstraZeneca shares opened at $187.50 apiece in New York, rising in early ...

Core Insights - PharmaTher Holdings Ltd. is pursuing Health Canada approval for generic semaglutide, aiming for commercialization following regulatory approval [1][4] - The expiration of regulatory exclusivity for semaglutide in Canada in January 2026 opens the market for generic competition [2] - The Canadian market for semaglutide generated approximately C$2.9 billion in sales in 2025, with potential growth in the broader GLP-1 receptor agonist market estimated at US$6.5 billion by 2033 [3] Company Strategy - PharmaTher's initiative focuses on speed-to-market, reliable supply, and broad dose coverage for generic semaglutide [4][7] - The company plans to leverage its experience from FDA approval of ketamine to execute its strategy for semaglutide [4] - A sterile injectable manufacturing strategy will be employed, utilizing a cost-effective, high-quality manufacturer with regulatory compliance [7] Market Context - The demand for semaglutide is increasing, and affordable access along with reliable supply will be critical in the Canadian market [4] - The transition in Canada's semaglutide market is seen as pivotal, with growing demand for generic options [2][4]

Summary of Aquestive Therapeutics Conference Call Company Overview - **Company**: Aquestive Therapeutics (NasdaqGM:AQST) - **Industry**: Pharmaceutical, specifically focused on the development of treatments for anaphylaxis Key Points and Arguments FDA Communication and Response Letter - The FDA issued a Complete Response Letter (CRL) regarding the Anaphylm Epinephrine Sublingual Film application, indicating that additional work is required before approval [5][12] - No deficiencies were cited regarding pharmacokinetic (PK) data, repeat dose safety, or sustainability of Anaphylm's performance [5][6] - Concerns were raised about packaging, use, administration, and labeling, collectively referred to as human factors [6][7] Human Factors and Clinical Studies - The FDA's human factors group expressed concerns about the ease of opening the pouch and potential tearing of the film during administration [7][8] - In a validation study, only one participant had difficulty opening the pouch, and instances of tearing did not prevent full dosing [8][9] - Feedback indicated that the film's administration location and potential chewing by users could lead to issues, although clinical studies showed no significant problems with tolerability [9][10] Resubmission Plans - A straightforward path to resubmission is anticipated by the third quarter of the year, with a focus on conducting a human factors validation study and a pharmacokinetic study [11][12] - The company aims to work with the FDA for a rapid review and approval process post-resubmission [12] Market and Launch Strategy - The market for epinephrine treatments is primarily dominated by autoinjectors, but there is a growing demand for alternatives like Anaphylm [16][17] - Market research indicates that 96% of patients prefer Anaphylm when comparing it to other products [17][18] - Plans for international filings in Canada and Europe are underway, with a focus on establishing distribution strategies [12][72] Recruitment and Sales Strategy - Recruitment for the sales team will be revisited closer to the approval date, with prior candidates being prioritized [70][71] - The company is preparing educational materials and demo units for healthcare providers to ensure proper administration of Anaphylm [75][77] Regulatory and Clinical Development - The company has had pre-submission meetings with Canadian and European health authorities, indicating a clear path forward for regulatory submissions [87] - Ongoing development of the Adrenoverse platform and AQST-108 will continue alongside efforts for Anaphylm [88][89] Additional Important Information - The absence of safety concerns in the CRL implies that the FDA is satisfied with the safety profile of Anaphylm [38][39] - The company is committed to improving packaging and instructions based on FDA feedback to enhance user experience [63][64] - The CRL has provided clarity on the path to approval, reducing uncertainties previously associated with the product [24][25] This summary encapsulates the critical aspects of the conference call, highlighting the company's current status, challenges, and future plans in the context of regulatory approval and market strategy.

Company Overview - Viatris Inc. (VTRS) has a market capitalization of $15.1 billion and operates globally across various regions including North America, Europe, Asia-Pacific, Africa, Latin America, and the Middle East, offering a wide range of branded, generic, complex, and biosimilar medicines [1] Stock Performance - Over the past 52 weeks, VTRS shares have increased by 14.6%, slightly outperforming the S&P 500 Index, which gained 14.3% during the same period [2] - Year-to-date, VTRS stock has returned 5.1%, compared to a 1.4% rise in the S&P 500 Index [2] Financial Performance - In Q3 2025, Viatris reported an adjusted EPS of $0.67 and revenue of $3.76 billion, exceeding expectations; however, shares fell nearly 6% due to a U.S. net loss of $128 million, attributed to a reduction in the fair value of its investment in Biocon Biologics and increased income tax expenses [6] - The decline in adjusted EPS was also influenced by the negative "Indore Impact," leading to an 11% drop compared to Q3 2024 [6] Earnings Forecast - For the fiscal year ending December 2025, analysts project a 12.5% year-over-year growth in adjusted EPS to $2.32 [7] - The earnings surprise history for Viatris is mixed, with the company exceeding consensus estimates in three of the last four quarters [7] Analyst Ratings - Among 10 analysts covering VTRS, the consensus rating is a "Moderate Buy," consisting of four "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [7] - Piper Sandler recently raised Viatris' price target to $12 while maintaining a "Neutral" rating, with a mean price target of $13.33 indicating a 1.8% premium to current price levels [8] - The highest price target of $16 suggests a potential upside of 22.2% from current levels [8]

Core Viewpoint - Sanofi has violated the UK pharmaceutical code of practice by making unsubstantiated claims regarding the effectiveness of its Beyfortus compared to Pfizer's RSV vaccine [1] Group 1: Company Actions - Sanofi's claims about Beyfortus being more effective than Pfizer's RSV vaccine have been deemed unsubstantiated by the industry's self-regulatory body [1] - The breach of the UK pharma code of practice indicates potential regulatory scrutiny and reputational risks for Sanofi [1] Group 2: Industry Implications - The incident highlights the importance of adhering to industry standards and regulations in pharmaceutical marketing [1] - This breach may lead to increased scrutiny of marketing practices across the pharmaceutical industry, particularly regarding comparative effectiveness claims [1]

Core Insights - IGC Pharma, Inc. has achieved approximately 70% of its planned patient enrollment in the Phase 2 CALMA clinical trial for IGC-AD1, targeting agitation associated with Alzheimer's disease [1] Company Progress - The company currently has around 23 active sites across 26 locations for the clinical trial [1] - Enrollment is actively progressing within this clinical network [1]

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a U.S. patent for a proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Group 1: Patent and Technology - The newly granted U.S. patent complements existing patents in the U.S. and Europe, reinforcing global intellectual property protection for NeuroThera's antimicrobial-potentiating platform [2]. - The patented technology combines established antibiotics with cannabinoids like Δ⁹-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), showing enhanced antimicrobial activity in pre-clinical studies against resistant Gram-positive pathogens such as MRSA [3][5]. - The platform aims to leverage the long-term safety data of these antibiotics to minimize risks while providing an effective and affordable therapeutic solution [3]. Group 2: Market Context and Need - Prolonged antibiotic use has led to the emergence of resistant bacterial strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, a significant increase from 57,000 deaths in 2019 [4]. - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The "antimicrobial-sparing" effect of NeuroThera's combination may reduce the need for new antibiotics, addressing serious side effects associated with resistance development and organ toxicity [7]. Group 3: Industry Challenges - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to long development timelines, high costs, and rapid bacterial resistance, leading to a decline in innovation in this field [8].

Core Insights - Identifying true value stocks requires thorough fundamental analysis beyond just key financial indicators like earnings per share and sales growth [1] Valuation Metrics - Investors often use valuation measures such as price-to-earnings (P/E) and price-to-sales (P/S) ratios, but the price-to-book (P/B) ratio is also a valuable tool for spotting attractively priced stocks with growth potential [2] - The P/B ratio is calculated as market capitalization divided by book value of equity, helping to identify low-priced stocks with high-growth prospects [2][6] - A P/B ratio of less than one indicates that a stock is undervalued, while a ratio greater than one suggests it may be overvalued [6][8] Book Value Definition - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities [4] - It is calculated by subtracting total liabilities from total assets, often equating to common stockholders' equity [5] Limitations of P/B Ratio - The P/B ratio is particularly useful for industries like finance and manufacturing but can be misleading for companies with significant R&D expenditures or high debt [9] - A P/B ratio of less than one may indicate weak returns on assets or overstated assets, while a ratio above one could suggest the stock is a takeover target [8][9] Screening Parameters - Stocks with a P/B ratio lower than the industry median are considered to have potential for price appreciation [12] - A lower P/S ratio compared to the industry average makes a stock more attractive [12] - A P/E ratio lower than the industry median is also a favorable indicator [13] - A PEG ratio of less than one indicates undervaluation with promising growth prospects [14] - Stocks should have a current price of at least $5 and a trading volume of over 100,000 for liquidity [15] Selected Low P/B Stocks - Invesco (IVZ) has a Zacks Rank of 1, a Value Score of B, and a projected 3-5 year EPS growth rate of 20.9% [16] - Harmony Biosciences (HRMY) holds a Zacks Rank of 1, a Value Score of A, and a projected 3-5 year EPS growth rate of 27.11% [17] - Concentrix (CNXC) has a Zacks Rank of 2, a Value Score of A, and a projected 3-5 year EPS growth rate of 8.76% [17] - Patria Investments Limited (PAX) has a Zacks Rank of 1, a Value Score of A, and a projected 3-5 year EPS growth rate of 15.39% [18] - Global Payments (GPN) has a Zacks Rank of 2, a Value Score of A, and a projected 3-5 year EPS growth rate of 11.54% [19]

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with GoodRx to provide savings of up to 30% on ARAKODA (tafenoquine) for eligible consumers [1][10] - ARAKODA is the only FDA-approved, once-weekly malaria prevention medication available in the U.S. market, making it a preferred choice for travelers to malaria-endemic regions [2][6] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [19] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [19] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in patients aged 18 and older and has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7][8] - The medication was discovered by the Walter Reed Army Institute of Research and has undergone extensive safety assessments in clinical trials [5][6] Partnership Details - The collaboration with GoodRx aims to lower out-of-pocket costs for patients and expand the marketing reach of ARAKODA, making it accessible at over 70,000 pharmacies nationwide [10][4] - Eligible patients can access a low self-pay price for ARAKODA through GoodRx starting February 2, 2026 [4][10]

1 These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans for Anaphylm; risk of del ...